## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 30 September 2004 (30.09.2004)

**PCT** 

## (10) International Publication Number WO 2004/082640 A2

(51) International Patent Classification7:

**A61K** 

(21) International Application Number:

PCT/US2004/008696

(22) International Filing Date: 19 March 2004 (19.03.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/455,566

19 March 2003 (19.03.2003)

- (71) Applicant (for all designated States except US): NEW CENTURY PHARMACEUTICALS, INC. [US/US]; 895 Martin Road, Huntsville, AL 35824 (US).
- (72) Inventors: and
- (75) Inventors/Applicants (for US only): CARTER, Daniel. C. [US/US]; 3131 Heatherhill Circle, Huntsville, AL 35802 (US). MCKENZIE, Simon, R. [US/US]; c/o New Century Pharmaceuticals, Inc., 895 Martin Road, Huntsville, AL 35824 (US). RUKER, Florian [US/US]; c/o New Century Pharmaceuticals, Inc., 895 Martin Road, Huntsville, AL 35824 (US).
- (74) Agent: SCHULMAN, Aaron, B.; Stites & Harbison PLLC, 1199 North Fairfax Street, Suite 900, Alexandria, VA 22314 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FRAGMENTS OR POLYMERS OF ALBUMIN WITH TUNABLE VASCULAR RESIDENCE TIME FOR USE IN THERAPEUTIC DELIVERY AND VACCINE DEVELOPMENT

(57) Abstract: An isolated fusion protein is provided which is a conjugate of a therapeutic polypeptide and an albumin fragment, such as a fragment including an individual domain or subdomain of albumin, or a polymer of albumin (e.g., dimers, trimers, etc.) and which is used to optimize the half-life of that therapeutic agent in the bloodstream in a tunable fashion based on the molecular weight of the fragment or polymer. Albumin fragments useful in the invention include fragments containing any of the individual domains and subdomains of human serum albumin, as well as fragments including specific combinations of binding regions or subdomains. The present invention thus provides fragments or polymers which will allow for optimizing half-lives of therapeutic polypeptides depending on their molecular weight, and this will optimizes protein and vaccine therapeutics to have desired half lives for their greatest effectiveness.